atrial fibrillation - catheter ablation - all type of patients clinical trials results meta-analysis

<h1> <a href="TM10-109-catheter ablation -atrial fibrillation" > <strong>atrial fibrillation</strong> - catheter ablation </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t8885.htm"> A4 (Jais), 2008 </a> <br> NCT00540787 </td> <td> catheter ablation<br>  <i>versus</i> <br> antiarrhythmic drugs </td> <td> patients with paroxysmal AF resistant to at least 1 antiarrhythmic drug. </td> <td> follow-up 12 months<br> n=53/59<br> Parallel groups<br> open <br> France,Canada, USA </td> </tr> <tr> <td> <a href="../TRC_t8887.htm"> Wazni , 2005 </a> <br> </td> <td> Pulmonary vein isolation<br>  <i>versus</i> <br> Flecainide, propafenone, or sotalol; amiodarone if needed </td> <td> Drug-naive monthly symptomatic AF >=3mo </td> <td> follow-up 12 months<br> n=32/35<br> Parallel groups<br> open <br> USA, Italy,Germany </td> </tr> <tr> <td> <a href="../TRC_t9537.htm"> APAF (Pappone), 2006 </a> <br> </td> <td> left atrial catheter ablation<br>  <i>versus</i> <br> Flecainide acetate, propafenone hydrochloride, or sotalol hydrochloride </td> <td> Drug-refractory paroxysmal AF >=6mo </td> <td> follow-up 12 months<br> n=99/99<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="../TRC_t9538.htm"> CAFCOAF (Stabile), 2006 </a> <br> </td> <td> left atrial catheter ablation plus amiodarone or other drugs<br>  <i>versus</i> <br> Amiodarone or other drugs </td> <td> Drug-refractory or drug-intolerant paroxysmal or persistent AF </td> <td> follow-up 12 months<br> n=68/69<br> Parallel groups<br> open blinded assessment <br> Italy </td> </tr> <tr> <td> <a href="../TRC_t9539.htm"> Krittayaphong, 2003 </a> <br> </td> <td> left atrial catheter ablation<br>  <i>versus</i> <br> amiodarone </td> <td> drug-refractory amiodarone-naive paroxysmal or persistent AF >=6mo </td> <td> follow-up 12 months<br> n=15/15<br> <br> open <br> Thailand </td> </tr> <tr> <td> <a href="../TRC_t9808.htm"> ThermoCool AF, 2008 </a> <br> NCT00116428 </td> <td> catheter ablation<br>  <i>versus</i> <br> antiarrhythmic drug therapy with a class I or III drug </td> <td> patients with AF who were nonresponsive to previous treatment with antiarrhythmic drugs </td> <td> follow-up 9 months<br> n=106/61<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9809.htm"> Oral, 2006 </a> <br> </td> <td> circumferential pulmonary-vein ablation and amiodarione<br>  <i>versus</i> <br> amiodarone and two cardioversions during the first three months alone </td> <td> patients with chronic atrial fibrillation </td> <td> follow-up 12 months<br> n=77/69<br> Parallel groups<br> open <br> Italy, USA </td> </tr> <tr> <td> <a href="../TRC_t9810.htm"> Forleo, 2009 </a> <br> </td> <td> pulmonary vein isolation<br>  <i>versus</i> <br> antiarrhythmic drug treatment </td> <td> patients with diabetes mellitus type 2 and paroxysmal or persistent AF </td> <td> follow-up 12 months<br> n=35/35<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="../TRC_t9811.htm"> Lakkireddy, 2006 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=138/139<br> Parallel groups<br> <br> USA </td> </tr> <tr> <td> <a href="../TRC_t9498.htm"> RESOLVE-AF, </a> <br> NCT00111488 </td> <td> Surgical Ablation with Microwave Energy<br>  <i>versus</i> <br> control </td> <td> patienst with permanent atrial fibrillation </td> <td> follow-up <br> n=200/0<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9534.htm"> MANTRA-PAF, </a> <br> NCT00133211 </td> <td> Radiofrequency Ablation<br>  <i>versus</i> <br> Medical Antiarrhythmic Treatment </td> <td> Paroxysmal Atrial Fibrillation </td> <td> follow-up 2 years<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t10348.htm"> CABANA, </a> <br> NCT00911508). </td> <td> left atrial catheter ablation<br>  <i>versus</i> <br> current state-of-the-art therapy with either rate control or rhythm control drugs </td> <td> patients with untreated or incompletely treated AF </td> <td> follow-up <br> n=3000/0<br> Parallel groups<br> open <br> </td> </tr> </table> <h2>References</h2> <p> <b>A4 (Jais), 2008 : </b> Jaïs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M, Extramiana F, Sacher F, Bordachar P, Klein G, Weerasooriya R, Clémenty J, Haïssaguerre MCatheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. <i>Circulation 2008 Dec 9;118:2498-505</i> [PMID 19029470] </p> <p> <b>Wazni , 2005 : </b> Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale ARadiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. <i>JAMA 2005;293:2634-40</i> [PMID 15928285] </p> <p> <b>APAF (Pappone), 2006 : </b> Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G, Mazzone P, Sora N, Greiss I, Santagostino A, LiVolsi L, Pappone N, Radinovic A, Manguso F, Santinelli VA randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. <i>J Am Coll Cardiol 2006;48:2340-7</i> [PMID 17161267] 10.1016/j.jacc.2006.08.037 </p> <p> <b>CAFCOAF (Stabile), 2006 : </b> Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P, Pascotto P, Fazzari M, Vitale DFCatheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). <i>Eur Heart J 2006;27:216-21</i> [PMID 16214831] 10.1093/eurheartj/ehi583 </p> <p> <b>Krittayaphong, 2003 : </b> Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, Pooranawattanakul S, Punlee K, Kangkagate CA randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. <i>J Med Assoc Thai 2003;86 Suppl 1:S8-16</i> [PMID 12866763] </p> <p> <b>ThermoCool AF, 2008 : </b> Wilber DJ, Pappone C, Neuzil P, et al. <i>Circulation 2008;118:2316 [abstract </i> [PMID ] </p> <p> <b>ThermoCool AF, 2008 : </b> Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DAComparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. <i>JAMA 2010;303:333-40</i> [PMID 20103757] </p> <p> <b>Oral, 2006 : </b> Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, Bates ER, Lehmann MH, Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady FCircumferential pulmonary-vein ablation for chronic atrial fibrillation. <i>N Engl J Med 2006;354:934-41</i> [PMID 16510747] 10.1056/NEJMoa050955 </p> <p> <b>Forleo, 2009 : </b> Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, De Sanctis V, Pappalardo A, Laurenzi F, Avella A, Casella M, Dello Russo A, Romeo F, Pelargonio G, Tondo CCatheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. <i>J Cardiovasc Electrophysiol 2009;20:22-8</i> [PMID 18775050] 10.1111/j.1540-8167.2008.01275.x </p> <p> <b>Lakkireddy, 2006 : </b> Lakkireddy DR, Patel D, Ryschon K, Thal S, Wazni O, Prasad S, et al. <i>J Am Coll Cardiol 2006;47:17A.</i> [PMID ] </p> <p> <b>Pappone, 2003 : </b> Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V, Tortoriello V, Sala S, Zangrillo A, Crescenzi G, Benussi S, Alfieri OMortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. <i>J Am Coll Cardiol 2003;42:185-97</i> [PMID 12875749] </p>